HQL

Tekla Life Sciences Investors

HQL, USA

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

https://www.teklacap.com/hql.html

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.5

Next Payout:

Jan 12, 2026

Yield:

11.7925 %
HQL
stock
HQL

Wolverine Asset Management LLC Purchases 72,601 Shares of abrdn Life Sciences Investors $HQL MarketBeat

Read more →
HQL
stock
HQL

Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details StreetInsider

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2025-03-31)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

6.01

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

1.24

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-11.93 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-11.48 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-5.74 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.04

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Tekla Life Sciences Investors

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-03-31

EPS Actual

-1.64

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-03-31)

Deep Value
Strong Deep Value(6.5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(2.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Fair GARP(4.5)
Growth
Moderate Growth(3.5)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-03-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-03-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-03-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.